Multiple Myeloma: Inside the Issue of Cereblon E3 Ligase Modulators

About this episode

Dr Natalie S Callander and Dr Paul G Richardson discuss the role of CELMoDs in managing multiple myeloma.

Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the potential role of CELMoDs in the management of multiple myeloma, supporting clinical data and ongoing investigations. CME information and select publications here .

People in this episode

Guests: Dr Natalie S Callander, Dr Paul G Richardson

Topics covered

• multiple myeloma
• Cereblon E3 ligase modulators
• clinical data
• cancer management
• ongoing investigations

Keywords

• multiple myeloma
• CELMoDs
• cancer treatment
• clinical trials
• E3 ligase modulators

Mentioned in this episode

Organizations: University of Wisconsin Carbone Cancer Center, Dana-Farber Cancer Institute

Products: CELMoDs

More episodes of Hematologic Oncology Update

• Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances · May 23, 2026 · 59 min
• Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances · April 20, 2026 · 59 min
• CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson · April 10, 2026 · 25 min
• Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 Review · April 1, 2026 · 25 min
• CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson · March 23, 2026 · 24 min
• Immune Thrombocytopenia — Microlearning Activity 3 with Dr Hanny Al-Samkari: ASH 2025 Review · March 21, 2026 · 29 min